XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Compre-hensive Income (Loss)
Balance at beginning of period (in shares) at Sep. 30, 2023     8,105,338      
Balance at beginning of period at Sep. 30, 2023 $ 233,073   $ 34,771 $ 199,386   $ (1,084) [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 12,004     12,004    
Other comprehensive income 339         339
Repurchase of common stock (in shares)     (112,117)      
Repurchase of common stock, net of tax $ (3,034)   $ (3,034)      
Exercise of stock options (in shares) 29,900   29,900      
Exercise of stock options $ 390   $ 390      
Common stock dividends (3,816)     (3,816)    
Stock-based compensation expense 211   $ 211      
Balance at end of period (in shares) at Mar. 31, 2024     8,023,121      
Balance at end of period at Mar. 31, 2024 238,679 $ (488) $ 32,338 207,086 $ (488) (745) [1]
Balance at beginning of period (in shares) at Dec. 31, 2023     8,120,708      
Balance at beginning of period at Dec. 31, 2023 237,369   $ 34,869 203,327   (827) [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 5,708     5,708    
Other comprehensive income 82         82
Repurchase of common stock (in shares)     (99,787)      
Repurchase of common stock, net of tax (2,672)   $ (2,672)      
Exercise of stock options (in shares)     2,200      
Exercise of stock options 35   $ 35      
Common stock dividends (1,949)     (1,949)    
Stock-based compensation expense 106   $ 106      
Balance at end of period (in shares) at Mar. 31, 2024     8,023,121      
Balance at end of period at Mar. 31, 2024 238,679 $ (488) $ 32,338 207,086 $ (488) (745) [1]
Balance at beginning of period (in shares) at Sep. 30, 2024     7,960,127      
Balance at beginning of period at Sep. 30, 2024 245,413 [2]   $ 29,862 215,531   20 [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 13,615     13,615    
Other comprehensive income (690)         (690)
Repurchase of common stock (in shares)     (89,168)      
Repurchase of common stock, net of tax (2,792)   $ (2,792)      
Restricted Stock Grants Forfeitures (in shares)     (1,830)      
Restricted stock grant forfeitures $ (11)   $ (11)      
Exercise of stock options (in shares) 34,360   34,360      
Exercise of stock options $ 686   $ 686      
Common stock dividends (3,980)     (3,980)    
Stock-based compensation expense 283   $ 283      
Balance at end of period (in shares) at Mar. 31, 2025     7,903,489      
Balance at end of period at Mar. 31, 2025 252,524   $ 28,028 225,166   (670) [1]
Balance at beginning of period (in shares) at Dec. 31, 2024     7,954,673      
Balance at beginning of period at Dec. 31, 2024 249,199   $ 29,593 220,398   (792) [1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 6,755     6,755    
Other comprehensive income 122         122
Repurchase of common stock (in shares)     (61,764)      
Repurchase of common stock, net of tax (1,908)   $ (1,908)      
Restricted Stock Grants Forfeitures (in shares)     (1,380)      
Restricted stock grant forfeitures (11)   $ (11)      
Exercise of stock options (in shares)     11,960      
Exercise of stock options 212   $ 212      
Common stock dividends (1,987)     (1,987)    
Stock-based compensation expense 142   $ 142      
Balance at end of period (in shares) at Mar. 31, 2025     7,903,489      
Balance at end of period at Mar. 31, 2025 $ 252,524   $ 28,028 $ 225,166   $ (670) [1]
[1] All amounts are net of income taxes.
[2] Derived from audited consolidated financial statements.